RNA: From the mes­sen­ger to the med­i­cine

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

In the 1990s, my col­leagues and I were gene hunters. In the years be­fore the hu­man genome was ful­ly se­quenced, we searched tire­less­ly for the ge­net­ic roots of dis­ease. It was a decades-long en­deav­or to first de­fine a syn­drome, then lo­cate the re­spon­si­ble gene, de­ter­mine its se­quence, study its mu­ta­tions and ma­nip­u­late it for ther­a­peu­tic ben­e­fit.

At the time, RNA sci­ence wasn’t be­ing se­ri­ous­ly con­sid­ered. DNA was our star, and RNA was a bit play­er.

It’s a dif­fer­ent sto­ry to­day, now that mR­NA vac­cines that were de­vel­oped in record time are pro­tect­ing mil­lions of peo­ple from a dan­ger­ous ill­ness. There is a dawn­ing aware­ness of the po­ten­tial for RNA-based med­i­cines. The CEO of the Bill & Melin­da Gates Med­ical Re­search In­sti­tute, Pen­ny Heaton, calls mR­NA vac­cines the be­gin­ning of “a new gold­en age of vac­ci­nol­o­gy.”

But she could have been even more op­ti­mistic. Be­cause af­ter decades of re­search in­to this nu­cle­ic acid that was once seen as a hum­ble as­sis­tant to DNA, RNA sci­ence is of­fer­ing new in­sights in­to in­tractable con­di­tions whose caus­es were pre­vi­ous­ly a mys­tery. It’s al­so un­lock­ing pow­er­ful new treat­ments.

Genes tell the body what to do. But if their code is gar­bled or in­com­pre­hen­si­ble, dis­ease will get the up­per hand. RNA—present in every cell in the body—is the mes­sen­ger of these im­por­tant in­struc­tions. These mes­sages (RNA tran­scripts) can be edit­ed to achieve a sub­stan­tial ther­a­peu­tic ef­fect, and this has im­pli­ca­tions in a wide range of de­gen­er­a­tive dis­eases.

It’s hard to be­lieve we ever viewed RNA as a poor re­la­tion to DNA. It’s not just a gold­en age for vac­cines that we have en­tered, it’s the be­gin­ning of a whole new era for med­ical sci­ence.

The op­por­tu­ni­ty

Hun­dreds of dis­eases can be traced to dys­func­tion­al pro­teins in the body. While DNA es­sen­tial­ly in­structs cells to cre­ate or reg­u­late these pro­teins in a way that pro­motes health and sur­vival, there are of­ten mis­prints, ty­pos, dele­tions and oth­er er­rors in DNA’s in­struc­tions. Con­se­quent­ly, the body some­times fails to pro­duce nec­es­sary pro­teins, pro­duces tox­ic pro­teins or fails to prop­er­ly reg­u­late pro­tein pro­duc­tion. This means dis­ease.

It al­so means the po­ten­tial for RNA-based med­i­cines, which seek to cor­rect these er­rors, is vast. And these treat­ments of­fer some­thing that gene ther­a­py or gene edit­ing does not: the abil­i­ty to make changes to cells that are re­versible and will not last a life­time.

Un­like gene ther­a­pies or gene edit­ing, RNA can be made to func­tion the way con­ven­tion­al drugs do. It can achieve a ther­a­peu­tic re­sult with­out mak­ing a per­ma­nent change to the pa­tient’s cells. Gene ther­a­pies or gene edit­ing risk cre­at­ing off-tar­get ef­fects in neigh­bor­ing cells and or­gans, which can be­come per­ma­nent changes. By con­trast, the body can shed an RNA ther­a­py the way it can shed the ef­fects of a drug.

The abil­i­ty of RNA to clar­i­fy DNA in­struc­tions to pro­mote hu­man health, with­out per­ma­nent al­ter­ations to a per­son’s cells, is why the po­ten­tial for RNA-based med­i­cines goes far be­yond de­vel­op­ing the next gen­er­a­tion of vac­cines. Biotech com­pa­nies are ex­plor­ing the many pos­si­bil­i­ties to­day.

One suc­cess­ful com­mon ap­proach in­volves “knock­ing down” dys­func­tion­al pro­teins that can lead to dis­ease, for ex­am­ple de­gen­er­a­tive con­di­tions like amy­otroph­ic lat­er­al scle­ro­sis (ALS) or meta­bol­ic dis­or­ders. Biotech com­pa­nies have been mak­ing in­roads on these con­di­tions by edit­ing RNA in­struc­tions to elim­i­nate a “gain-of-func­tion” pro­tein. In these cas­es, weak­en­ing the pro­duc­tion of cer­tain tox­ic pro­teins lessens the dis­ease im­pact.

Oth­er com­pa­nies are aim­ing not to elim­i­nate pro­teins but sim­ply al­ter their pro­duc­tion by splic­ing the pre-mR­NA that pro­vides their in­struc­tion guide and di­rec­tions for reg­u­la­tion. This is the case at Sarep­ta, where I pre­vi­ous­ly served as CEO and chief med­ical of­fi­cer.

The com­pa­ny I lead now, Stoke Ther­a­peu­tics, is pi­o­neer­ing a whole dif­fer­ent RNA ap­proach. Stoke is fo­cused on hap­loin­suf­fi­cien­cies or dis­eases like Dravet syn­drome (a se­vere and pro­gres­sive ge­net­ic epilep­sy) and au­to­so­mal dom­i­nant op­tic at­ro­phy that are caused by “loss of func­tion” mu­ta­tions in one copy of a gene, which re­sult in in­suf­fi­cient pro­tein lev­els that are es­sen­tial to hu­man health. Rather than knock­ing down the dys­func­tion­al gene, as oth­er com­pa­nies seek to do, Stoke is de­sign­ing RNA-based med­i­cines to in­crease ex­pres­sion of the prop­er­ly func­tion­ing gene in the pair, “up-reg­u­lat­ing” its pro­tein pro­duc­tion and there­by com­pen­sat­ing for the non-func­tion­al copy of the gene. By se­lec­tive­ly restor­ing, or “stok­ing”, the pro­duc­tion of the nat­u­ral­ly oc­cur­ring pro­tein, Stoke’s TAN­GO (Tar­get­ed Aug­men­ta­tion of Nu­clear Gene Out­put) ap­proach has the po­ten­tial to ad­dress the un­der­ly­ing ge­net­ic cause of hap­loin­suf­fi­cient dis­eases.

RNA sci­ence is even carv­ing out a pres­ence in di­ag­nos­tics, with RNA analy­sis of liq­uid biop­sy for can­cer en­abling ear­li­er di­ag­no­sis.

Vac­cines did not ush­er in a whole new era of RNA-based med­i­cine. But they shined a light on this area, which has been de­vel­op­ing steadi­ly for two decades, and which is open­ing the door to a seem­ing­ly end­less ar­ray of ap­pli­ca­tions, dis­ease states and treat­ment path­ways that, once ex­plored, will al­ter how we un­der­stand and treat ge­net­ic dis­eases.

The need

Be­fore I took the helm at biotech­nol­o­gy com­pa­nies, I treat­ed pa­tients at the point of care. Most of my pa­tients were chil­dren with rare dis­eases.

I have seen what ge­net­ic dis­eases can do, and I know the frus­tra­tion that comes with talk­ing to par­ents about id­io­path­ic con­di­tions that de­grade their chil­dren’s qual­i­ty of life – or worse. Id­io­path­ic means we just can’t shed much light on the cause of dis­ease, even when its ef­fects are all too vis­i­ble. For a doc­tor, the frus­tra­tion that came with di­ag­no­sis and treat­ment of id­io­path­ic con­di­tions was too in­tense to de­scribe.

One of the great things about this new era of ge­net­ic med­i­cine we are liv­ing in is that we now know far more about the caus­es of dis­ease. Many con­di­tions are in­her­it­ed.

But too of­ten, un­der­stand­ing the cause has not led to a cure or even a less­en­ing of the con­di­tion. Gene ther­a­py and gene edit­ing have shown ini­tial promise, but we need ad­di­tion­al strate­gies if we are to trans­late ful­ly our in­creased un­der­stand­ing of dis­ease in­to pow­er­ful treat­ments.

RNA is the next leg of this ex­cit­ing jour­ney. As DNA’s tran­scriber and mes­sen­ger, its use in med­i­cine brings us clos­er to stop­ping dis­eases of all kinds right at their source.

The Fac­tors Dri­ving a Rapid Evo­lu­tion of Gene & Cell Ther­a­py and CAR-T Clin­i­cal Re­search in APAC

APAC is the fastest growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies globally, with China leading in the region. 

APAC is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022. The number of CAR-T trials initiated by Western companies has rapidly increased in recent years (current CAGR of about 60%), with multiple targets being explored including CD19, CD20, CD22, BCMA, CD30, CD123, CD33, CD38, and CD138.

The End­points 11; blue­bird's $3M gene ther­a­py; Bio­gen tout new neu­ro da­ta; Harsh re­views for can­cer drugs; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Reading about John Carroll’s pick of biotech’s most promising startups has become a treasured tradition. If you ever get curious about previous classes of the Endpoints 11, you can find all of them (plus a number of our other regular specials) here.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.

EMA warns of short­ages of two Boehringer heart drugs due to a spike in de­mand

The EMA is putting EU member states on alert over the shortage of two drugs that counter heart attacks due to an uptick in demand.

On Friday, the EMA sent out a warning that two Boehringer Ingelheim drugs are experiencing a shortage: Actilyse and Metalyse. The drugs are used as emergency treatments for adults experiencing acute myocardial infarction, or a heart attack, by dissolving blood clots that have formed in the blood vessels.

The End­points 11: The top pri­vate biotechs in pur­suit of new drugs. Push­ing the en­ve­lope with pow­er­ful new tech­nolo­gies

Right around the beginning of the year, we got a close-up look at what happens after a boom ripples through biotech. The crash of life sciences stocks in Q1 was heard around the world.

In the months since, we’ve seen the natural Darwinian down cycle take effect. Reverse mergers made a comeback, with more burned out shells to go public at a time IPOs and road shows are out of favor. And no doubt some of the more recent arrivals on the investing side of the business are finding greener pastures.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Solicitor General Elizabeth Prelogar

Should SCO­TUS hear Am­gen's Repatha case? So­lic­i­tor gen­er­al says no

Back in April, Amgen said it was encouraged by the solicitor general’s anticipated review of its Supreme Court petition to rehear a Repatha patent case. They’re likely much less optimistic about the outcome now.

Solicitor General Elizabeth Prelogar wrote in a recent 27-page brief that Amgen’s arguments “lack merit and further review is not warranted.”

The case traces back to a suit filed in 2014 against Sanofi and Regeneron’s Praluent, which ended up beating Amgen’s PCSK9 blockbuster Repatha to market by a month just a year later.

As­traZeneca, Mer­ck cull one Lyn­parza in­di­ca­tion in heav­i­ly pre­treat­ed ovar­i­an can­cer pa­tients

Just one day after blockbuster Lynparza got access to another indication in China, its Big Pharma owners have decided to withdraw it in certain patients after reviewing Phase III data.

The two companies that work together on Lynparza decided to recall one of the indications several weeks ago in a specific type of ovarian cancer, Lynparza’s first indication when it was first FDA-approved in 2014. Initial data showed that rates of overall survival in patients with at least three rounds of chemo before getting on the PARP inhibitor were lower than in patients with less previous chemo treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.

Fu­ji­film con­tin­ues CD­MO ex­pan­sion, break­ing ground on $435M UK site

Fujifilm’s CDMO arm, Fujifilm Diosynth, has been on a roll this month as the company has recently broken ground on a major project in Europe and it appears to be keeping up the momentum.

Fujifilm Diosynth announced that it has kicked off an expansion project for its microbial manufacturing facility at its campus in the town of Billingham, UK, in the northeast of England.

The 20,000 square-foot, £400 million ($435 million) expansion will add clean rooms, purification suites and a packing area along with more space for the manufacturing itself.

An­oth­er Cipla site lands a Form 483 over clean­ing is­sues and QC con­trols

A Cipla drug manufacturing site in India has once again landed in the crosshairs of FDA inspectors.

The facility in question is Cipla’s drug manufacturing facility in the village of Verna, in the state of Goa in India’s southwest. In a sign that foreign inspections might ramp up again, the FDA’s visit from Aug. 16 to Aug. 22 uncovered six observations.

The 11-page report noted that environmental monitoring at the site did not properly ensure that microbial contaminants were not making any impact in the aseptic filling areas. It also found that procedures meant to stop microbial contamination were not adequately conducted in aseptic areas of the facility.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.

FDA ad­comm takes down Se­cu­ra Bio's leukemia drug af­ter fi­nal tri­al re­sults show po­ten­tial OS detri­ment

The FDA’s Oncologic Drugs Advisory Committee on Friday voted 8-4 against the benefit-risk profile of Secura Bio’s PI3K inhibitor Copiktra (duvelisib), which won approval in September 2018 as a third-line treatment for relapsed or refractory CLL or SLL, but updated pivotal trial results raised safety questions.

In addition to the serious and fatal toxicities of duvelisib, FDA speakers at the ODAC meeting pointed to an evolved treatment landscape for CLL and SLL, with targeted BTK or BCL2 inhibitors (front-line or second-line), and data pointing to a “potential detriment” in overall survival for duvelisib. But some ODAC members noted that the detriment was likely small and that there is some efficacy even as the data are difficult to interpret.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.